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INTRODUCTION
Newborn screening (NBS) for inborn errors of metabolism is a 
worldwide public health program implemented to screen as-
ymptomatic newborns for rare inherited diseases for which ear-
ly treatment results in significant reductions in morbidity and 
mortality. NBS methods have evolved in recent years, especially 
with the development of tandem mass spectroscopy (MS/MS), 
which now facilitates the identification of many disorders in 
parallel using a single assay.1,2 In Korea, NBS for over 50 diseas-
es has been supported free of cost by a national program since 
November 2018. 
However, current NBS programs show high rates of false-pos-
itive results (FPRs). In addition, tests performed on sick, prema-
ture, and/or low birth weight infants that require hospitalization 
in a neonatal intensive care unit (NICU) result in higher FPRs, 
requiring repeated NBS and additional follow-up tests, which 
can significantly delay diagnosis and treatment of sick neonates.3,4 
Thus, there is a need for faster intervention and special planning 
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for the neonate population to make more accurate and timely 
diagnoses. However, few studies have addressed the best ways 
to reduce the FPR of conventional NBS in the NICU. The Clini-
cal and Laboratory Standards Institute has recommended that 
infants suspected to have a metabolic disorder should undergo 
a follow-up NBS test to be performed only after ceasing total 
parenteral nutrition (TPN) or medical therapies initiated owing 
to an abnormal NBS. However, rapid diagnosis using conven-
tional NBS methods for early intervention remains a challenge 
in stressed neonates.5,6 The recent advent of next-generation se-
quencing (NGS) technology has enabled more effective diag-
nosis of monogenic disorders for suspected specific diseases 
in newborns by using phenotype-based NGS panels or whole 
exome sequencing.4,7-9  
However, the main goal of NBS is to screen all neonates and 
allow for the early detection of affected infants to prevent seri-
ous clinical concerns prior to their discharge from the hospital. 
Inborn errors of metabolic disorders are rare genetic disorders, 
some of which cannot be identified by tandem mass spectrom-
etry. Therefore, few studies have aimed to determine whether 
molecular diagnostics can be used to replace NBS: the Babyseq 
Project supported by Newborn sequencing in Genomic Medi-
cine and Public Health is the most representative study, with 
127 healthy newborns and 32 newborns admitted to NICU who 
were not preselected for specific diseases. Replacing NBS with 
molecular screening remains a challenge owing to variant anal-
ysis, interpretation, and reporting for adult-onset disorders from 
genomic data.10,11 In this study, we describe the useful implemen-
tation of a targeted NGS panel including childhood-actionable 
genes to complement the problem of delayed diagnosis with 
conventional NBS tests for high-risk neonates without pre-se-
lection of specific phenotypes in the NICU.
MATERIALS AND METHODS
Ethical considerations
The study was approved by the Institutional Review Board of 
Yonsei University Health System (IRB, 42017-0127). Korean ne-
onates or infants who were admitted to the NICU at Severance 
Children’s Hospital (Seoul, Korea) from May 2017 to September 
2017 were included in the study after obtaining written informed 
consent from at least one biological parent/guardian. None of 
the babies was selected for metabolic disorders in line with the 
population-based NBS program.
Sample preparation, sequencing, and analysis of the 
TNGS panel and NBS
A TNGS panel for neonatal diseases was designed and validat-
ed in a previous study.12 A targeted gene enrichment method was 
used to construct libraries for subsequent determination of se-
quences using an NGS method with HiSeq2000 (Illumina, San 
Diego, CA, USA). In this study, the probe set was designed to 
capture 1.45 Mb, covering the exons and 25 nucleotides at the 
flanking introns for 198 targeted genes (Supplementary Table 1, 
only online). Probe-library hybridization followed by capture of 
target genes was performed according to the manufacturer’s in-
structions. 
A total of 48 samples were registered for the TNGS panel, which 
when run together using the developed panel of a 1-Mb region 
with a 1-Gb output would likely cover ≤×500 reads. We used blood 
samples collected on filter paper, and DNA was isolated from 
dried blood spots with QIAamp DNA Mini Kits (Qiagen, Valen-
cia, CA, USA). The DNA was enzyme-fragmented with NEBNext 
dsDNA Fragmentase® (New England Biolabs, Ipswich, MA, USA), 
which was used to construct sequence libraries, according to the 
protocol provided by Cellemix (Seoul, Korea). For library enrich-
ment, we used a custom probe set synthesized by Cellemix (Seoul). 
The subsequent capturing procedure was performed with the 
MYbaits® kit (Arbor Biosciences, Ann Arbor, MI, USA), and se-
quencing was performed on a HiSeq 2000 system (Illumina). 
BaseSpace (Illumina) was used for data processing, alignment, 
variant calling, and annotations. The average coverage of target 
bases was 99.8%, with 98.1% of the regions of interest having at 
least 10X coverage and 95.4% having at least 20% coverage (Sup-
plementary Table 2, only online). The sequenced reads were 
mapped to the human reference genome (UCSC hg19) with 
Burrows-Wheeler Aligner (BWA-0.7.7-isis-1.0.0), and variants 
were identified with the Genome Analysis toolkit (GATK version 
1.6.23-gf0210b3). After filtering out variants using an internal 
database, variants with a minor allele frequency of less than 1% 
in either the 1000 Genomes Project or Exome Aggregation Con-
sortium database were assessed further. The criteria for classifi-
cation of variants were based on the principle recommended 
by the American College of Medical Genetics and Genomics 
(ACMG) standards.13 
In Korea, NBS is mandated by law, and initial NBS samples 
were collected based on conventional processes within 7 days 
with TNGS samples consecutively. For newborns weighing less 
than 2000 g or those starting TPN, repeated screening tests for 
28 days after birth or before discharge were required. Abnormal 
NBS was conducted once more and considered presumptive-
ly positive. Additional biochemical tests were then performed 
based on ACMG ACT sheets (https://www.acmg.net), and medi-
cal records were reviewed. 
RESULTS
Participant demographics
To evaluate the usefulness of the TNGS panel in NBS for neo-
nates showing high numbers of FPRs, we tested 48 clinical sam-
ples for newborn diseases associated with 198 genes (Supple-
mentary Table 1, only online). The individual participants in the 
NICU were not selected for metabolic diseases in advance and 
included both full-term and preterm infants. In this study, there 
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were 18 (38%) preterm infants and 27 (56%) newborns with a 
birth weight of less than 2000 g (Table 1). The average birth weight 
was 1998 g (range: 610–3790 g). 
In our hospital, additional NBS tests are routinely performed 
to obtain more reliable results when babies have had 48 h of 
oral feeding after TPN is discontinued. Among the infants in the 
NICU that underwent additional NBS, those born with low birth 
weight (<2000 g) and preterm babies were assessed at later ages 
(days since birth) than full-term neonates to minimize the FPRs 
(Table 1). 
Variants in the TNGS panel
The clinical characteristics of all newborns included in this pilot 
study are summarized in Supplementary Table 3 (only online). 
A total of 25 variants were identified in 19 patients (Table 2). 
In accordance with ACMG guidelines, 13 variants classified as 
“likely pathogenic” or “pathogenic” were detected in 11 (22.9%) 
of the neonates. In Korea, an extended NBS test using MS/MS 
was performed to detect approximately 54 metabolic diseases 
in a conventional NBS program. However, we identified patho-
genic or likely pathogenic variants reported in six genes, includ-
ing those associated with metabolic diseases not covered in 
the NBS: DHCR7 (Smith-Lemli-Opitz syndrome), PCBD1 (BH4-
deficient hyperphenylalaninemia), GAA (glycogen storage dis-
ease II), ALDOB (fructose intolerance, hereditary), ATP7B (Wil-
son disease), and GBA (Gaucher disease). Two pathogenic GAA 
variants were identified in patient D17; however, those alleles 
were found in the same strand in the raw data and were negative 
in the enzyme analysis, suggesting a diagnosis as a carrier of 
Pompe disease. Of the known pathogenic mutations of the CY-
P21A2 gene, p. Gln319Ter is one of the most common variants 
related to congenital adrenal hyperplasia in Koreans, and the 
heterozygote mutation was identified in two unrelated patients 
in this study.14 One of the patients, D30, a female with ambigu-
ous genitalia, showed normal 17-OHP levels in the NBS screen-
ing test, and the electrolyte balance was also normal. The other 
newborn, D43, was a male who underwent a colostomy opera-
tion due to a congenital imperforate anus.
Three of the newborns (D01, D03, D04) showed positive re-
sults in a comprehensive NBS. In the case of D01, elevation of C4 
using MS/MS resulted in suspicion of an isobutyl-CoA dehydro-
genase (IBDH) deficiency and short-chain acyl-CoA dehydro-
genase deficiency. According to the ACMG algorithm, ethylma-
lonic encephalopathy (associated with the ETHE1 gene) is one 
of the diseases included in the differential diagnosis NBS.15 As 
a result, two mutations in ACAD8 were identified in patient D01, 
and the patient was ultimately diagnosed with IBDH deficiency 
associated with a novel compound heterozygous variant. For 
patients D03 and D04, increases in C5-OH acylcarnitine (3-OH 
isovalerylcarnitine) were reported to result in the same suspect-
ed disease of 3-methylcrotonyl-CoA carboxylase deficiency in-
herited in an autosomal recessive pattern. However, in the for-
mer patient, a heterozygote mutation (NM_020166.3: c.1391A>C; 
p. His464Pro) was identified in the MCCC1 gene, which is re-
ported to be benign. In the latter case, D04, one unknown vari-
ant of the MCCC1 gene was identified and classified as a vari-
ant of unknown significance. In addition, biotinidase deficiency 
(associated with the BTD gene), which is one of the diseases caus-
ing elevated C5-OH, is not included in the Korean screening pro-
gram at present, but could be evaluated through the TNGS pan-
el. However, in patient D04, considering the limitations of not 
finding additional variants, such as deletion or duplication, it is 
necessary to confirm the clinical characteristics of the patient, 
and additional biochemical tests may be needed. Ultimately, the 
abnormal NBS tests were considered presumptively false-pos-
itive in these two asymptomatic patients based on assessment 
with the TNGS panel. 
DISCUSSION
In this pilot study, we used a TNGS panel as a supplementary 
method for the conventional NBS program to achieve early di-
agnosis and to determine cases of false positive and carrier sta-
tus in newborns in the NICU. This expands the applications of a 
few previous studies in which genetic confirmation tests were 
used only for neonates with abnormal NBS results or symptom-
atic disorders.3,7,16,17 
Table 1. Demographic Characteristics of Patients (n=48)
N (%) Age for additional newborn screening (days since birth) (mean±SD) p value
Gender 0.828
Male 28 (58) 22.7±29.1
Female 20 (42) 22.1±15.7
Gestation age (23–41 weeks) <0.001
Full-term 30 (62) 7.2±5.5
Preterm 18 (38) 31.8±26.3
Birth weight 0.001
<1000 g 11 (23) 40.3±13.9
1000–2000 g 16 (33) 31.4±34.8
2000–4000 g 21 (44) 10.4±9.0
SD, standard deviation.
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The NBS program is a public health program in Korea aimed 
at screening every neonate for inherited metabolic disorders 
and was introduced to identify conditions that can be critical to 
a child’s health and survival. However, the screening program 
often produces high number of FPRs, which means that a baby 
with a suspected diagnosis may not always have health prob-
lems. To correctly identify all affected neonates, a confirmatory 
test, including biochemical analyses, enzyme activity, and geno-
typing, is required for positive results determined with NBS. In 
addition, FPRs (about 5–20%) are more common for infants in 
the NICU, or those with low birth weight, that are ill, and on TPN, 
which require additional follow-up NBS and confirmatory test-
ing. The FPRs were reported to be 13-fold higher in very low birth 
weight infants (1000 to 1499 grams), and at least one in 10 of those 
infants showed FPRs with NBS. If the blood collection is delayed 
until the infant is completely off TPN, it could result in delayed 
diagnosis for an infant born with a low birth weight and/or pre-
term baby in NICU.3-5 
To resolve these issues, we introduced TNGS to screen stressed 
newborns in the NICU undergoing the constitutional NBS pro-
gram (Supplementary Fig. 1, only online).5,6,15 Dried blood spot 
samples initially collected from these infants at high risk of 
FPRs were sent for NBS and the TNGS panel simultaneously. 
NBS was conducted based on the ACMG ACT sheet and algo-
rithm as the conventional test, followed by interpretation of ge-
netic variants according to ACMG standards. When pathogen-
ic, likely pathogenic, or variants of unknown significance were 
identified in the infants, the concordance between other confir-
matory tests, such as biochemical tests, and variant classifica-
tion was evaluated. 
This is the first application of the TNGS panel in conjunction 
with conventional population-based NBS for infants in the NICU 
to reduce the rate of FPRs and diagnose the precise metabolic 
disorder. This application might have broad implications for 
changing practice in the NICU or cardiac intensive care unit to 
enable a faster diagnosis and thus allow for more timely inter-
vention. In addition, the repetitive testing without an accurate 
diagnosis of suspected disease imposes a huge amount of stress 
on the family because metabolic disorders can be fatal in some 
cases. Moreover, individuals with one copy of a recessive allele 
could be identified with the TNGS panel, allowing for identifi-
cation of carriers with an asymptomatic condition that might 
warrant regular follow-up.
A definitive diagnosis was made in only one (D01) of the 48 
infants included in this pilot study, which reflects the overall rar-
ity of metabolic disorders. IBHD deficiency is an inborn error of 
valine metabolism with increased C(4)-carnitine levels, as iden-
tified by MS/MS. Most cases of IBHD deficiency were asymp-
tomatic, and very few affected patients presented anemia, fail-
ure to thrive, dilated cardiomyopathy, and plasma carnitine 
deficiency. The patient D01 showed no related symptoms, and 
regular check-ups were performed. Because the range of symp-
toms of IBHD deficiency remains unclear, an exact diagnosis re-
quires both NBS and molecular testing, such as TNGS. Two as-
ymptomatic infants (D03 and D04) yielded FPRs, and the suspected 
diagnosis from the NBS was ruled out based on the mutations 
detected. However, patients with rare metabolic disorders some-
times have highly variable phenotypes, and hence, patients with 
abnormal NBS results should follow up their clinical symptoms 
and consider further evaluation if necessary. 
Overall, FPRs and diagnostic yields of NBS cannot be estimat-
ed with this limited sample size. Moreover, the diagnostic yield 
seems relatively low because the actionable child-onset-genes 
related to NBS was designed for diagnosis of a rare genetic dis-
order with low incidence before clinical symptoms occurred. 
Also, newborns enrolled in this study were not limited to patients 
suspected of specific metabolic diseases, which is the first valu-
able pilot study showing that TNGS can be used to address the 
disadvantage of NBS screening. If the patients show clinical symp-
toms for suspected metabolic or genetic disorders while wait-
ing for results of the TNGS test, the early diagnostic yield could 
be increased through a trio-based NGS test involving family his-
tory or parental samples.
In Korea, although the government-sponsored NBS program 
using MS/MS can screen over 50 diseases, some critical inher-
ited disorders, such as glycogen storage disease, lysosomal stor-
age disorder, severe combined immune deficiency disorder, ad-
renoleukodystrophy, and ornithine deficiency are not included. 
Therefore, rare metabolic disorders and several genetic disor-
ders affecting infants and children could be screened before the 
onset of clinical signs using the TNGS panel. 
Integration of our TNGS panel with NBS might help to avoid 
incidental findings and later-onset diseases rather than con-
ducting whole-genomic sequencing at birth as part of the NBS 
program, and the specific genes included in the panel could be 
designed considering regional incidences based on ethnic back-
ground.18,19 However, there is still room for improvement in the 
current TGNS panel, which does not cover deletion/duplication 
variants and deep intronic or promoter variations sufficiently, 
potentially resulting in increased false negative results. We also 
found that compound heterozygote conditions cannot be de-
tected by the TNGS panel alone, owing to the technical limitation 
of distinction between cis or trans variants, except for mutations 
that are located very close to each other. as in infant D17. 
Despite these limitations, we demonstrated that screening of 
ill infants with a TNGS panel could reduce delayed diagnoses, 
even for those at high risk of FPRs, using the current national NBS 
program. Moreover, disorders not detected in the current NBS 
can be diagnosed with the TNGS panel. The proposed practical 
workflow for conducting the TNGS panel analysis concurrent-
ly with initial NBS in stressed babies is expected to substantial-
ly reduce the number of unnecessary repetitive NGS tests and al-
low for the faster detection of rare metabolic disorders in infants.
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